251 related articles for article (PubMed ID: 24200993)
21. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
22. Allosteric Modulation of Kv11.1 (hERG) Channels Protects Against Drug-Induced Ventricular Arrhythmias.
Yu Z; Liu J; van Veldhoven JP; IJzerman AP; Schalij MJ; Pijnappels DA; Heitman LH; de Vries AA
Circ Arrhythm Electrophysiol; 2016 Apr; 9(4):e003439. PubMed ID: 27071825
[TBL] [Abstract][Full Text] [Related]
23. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
24. Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking.
Han S; Zhang Y; Chen Q; Duan Y; Zheng T; Hu X; Zhang Z; Zhang L
Eur J Pharmacol; 2011 Jan; 650(1):138-44. PubMed ID: 20951697
[TBL] [Abstract][Full Text] [Related]
25. Correlation between human ether-a-go-go-related gene channel inhibition and action potential prolongation.
Saxena P; Hortigon-Vinagre MP; Beyl S; Baburin I; Andranovits S; Iqbal SM; Costa A; IJzerman AP; Kügler P; Timin E; Smith GL; Hering S
Br J Pharmacol; 2017 Sep; 174(18):3081-3093. PubMed ID: 28681507
[TBL] [Abstract][Full Text] [Related]
26. Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.
Huang XP; Mangano T; Hufeisen S; Setola V; Roth BL
Assay Drug Dev Technol; 2010 Dec; 8(6):727-42. PubMed ID: 21158687
[TBL] [Abstract][Full Text] [Related]
27. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells.
Zhao J; Wang Q; Xu J; Zhao J; Liu G; Peng S
Eur J Pharmacol; 2011 Jun; 660(2-3):259-67. PubMed ID: 21497594
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade.
Chaudhary KW; O'Neal JM; Mo ZL; Fermini B; Gallavan RH; Bahinski A
Assay Drug Dev Technol; 2006 Feb; 4(1):73-82. PubMed ID: 16506891
[TBL] [Abstract][Full Text] [Related]
29. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.
Zhou J; Augelli-Szafran CE; Bradley JA; Chen X; Koci BJ; Volberg WA; Sun Z; Cordes JS
Mol Pharmacol; 2005 Sep; 68(3):876-84. PubMed ID: 15976038
[TBL] [Abstract][Full Text] [Related]
30. F463L increases the potential of dofetilide on human ether-a-go-go-related gene (hERG) channels.
Cheng G; Wu J; Han W; Sun C
Microsc Res Tech; 2018 Jun; 81(6):663-668. PubMed ID: 29573040
[TBL] [Abstract][Full Text] [Related]
31. Interactions at human ether-à-go-go-related gene channels.
Friemel A; Zünkler BJ
Toxicol Sci; 2010 Apr; 114(2):346-55. PubMed ID: 20071423
[TBL] [Abstract][Full Text] [Related]
32. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
33. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
34. The evolutionarily conserved residue A653 plays a key role in HERG channel closing.
Stepanovic SZ; Potet F; Petersen CI; Smith JA; Meiler J; Balser JR; Kupershmidt S
J Physiol; 2009 Jun; 587(Pt 11):2555-66. PubMed ID: 19406877
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on HERG potassium channels.
Zhao J; Lian Y; Lu C; Jing L; Yuan H; Peng S
J Ethnopharmacol; 2012 Jun; 141(2):685-91. PubMed ID: 21920426
[TBL] [Abstract][Full Text] [Related]
36. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Di Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H104-17. PubMed ID: 23103500
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil.
Vicente J; Johannesen L; Mason JW; Crumb WJ; Pueyo E; Stockbridge N; Strauss DG
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25870186
[TBL] [Abstract][Full Text] [Related]
38. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
Yang BF; Xu DH; Xu CQ; Li Z; Du ZM; Wang HZ; Dong DL
Acta Pharmacol Sin; 2004 May; 25(5):554-60. PubMed ID: 15132818
[TBL] [Abstract][Full Text] [Related]
39. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
40. Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels.
Chiu PJ; Marcoe KF; Bounds SE; Lin CH; Feng JJ; Lin A; Cheng FC; Crumb WJ; Mitchell R
J Pharmacol Sci; 2004 Jul; 95(3):311-9. PubMed ID: 15272206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]